Navigation Links
Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Date:11/13/2012

Mountain View, California; November 13, 2012. Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome." Four clinical trial sites have been selected in the United States: Lucile Packard Children's Hospital, Stanford University Medical Center Palo Alto, California; Akron Children's Hospital Akron, Ohio; Seattle Children's Hospital Seattle, Washington; and Texas Children's Hospital, Baylor University Houston, Texas.

The trial is a placebo-controlled study lasting six months, and then extending an additional six months, during which all subjects will receive EPI-743. Subjects must be between one and twelve years old, possess genetic confirmation of Leigh syndrome, and meet certain disease severity criteria. More information on the study specifics is available on ClinicalTrials.gov.

The primary endpoint of the clinical trial is the Newcastle Paediatric Mitochondrial Disease Scale. Secondary endpoints include neurologic, muscular, imaging, and biomarker indices. The study design was based on positive phase 2A data recently reported in the journal Molecular Genetics and Metabolism, "EPI-743 reverses the progression of the pediatric mitochondrial disease- genetically defined Leigh Syndrome" 107 (2012) 383-388.


'/>"/>

Contact: Lorraine Gilmore
Lgilmore@edisonpharma.com
650-641-9202
Edison Pharmaceuticals, Inc.
Source:Eurekalert

Page: 1

Related medicine news :

1. Environmentally friendly chemistry important for manufacturing pharmaceuticals
2. Scientists use sound waves to levitate liquids, improve pharmaceuticals
3. Plastic and Reconstructive Surgery Journal announces global expansion initiatives
4. NY-Presbyterian Hospital announces participation in trial for hard-to-treat hypertension
5. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
6. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
7. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
8. SfN announces winners of brain awareness video contest
9. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
10. NYU School of Medicine announces new clinical trial for ulcerative colitis
11. ASTRO announces 2012 fellows class
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... measurement firms. The ranking is based on reported data for 2015 performance ... health systems, ambulatory surgical centers, clinically integrated networks, and many of the nation’s ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing ... Bear Cancer Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support ... Obispo counties. To assist TBCF, the NALA recently hosted a Thanksgiving food drive that ...
(Date:12/6/2016)... ... December 06, 2016 , ... Healthcare leaders from ... regulations at the 7th annual Health IT Leadership Summit, to be held Wed., ... for the Centers for Medicare & Medicaid Services (CMS), will be the morning ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is proud to announce it has added CXC Solutions (CXC) as a new ... These solutions are tailored to help benefits advisors reduce operating costs and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving ... and development, largely due to its potential for revolutionizing human disease treatment. There ... human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... NEW YORK , Dec. 5, 2016 Special ... collection of samples such as fluid and cells from organs ... advanced features, shapes, and sizes. The global market for special ... increasing geriatric population. In terms of revenue, the global special ... of 7.4% during the forecast period (2016–2026) and is expected ...
(Date:12/5/2016)... THE WOODLANDS, Texas , Dec. 5, 2016 /PRNewswire/ ... ) announced top-line results today from a Phase 2 ... inhibitor, conducted by Lexicon in collaboration with JDRF, the ... The purpose of this Phase 2 clinical trial, ... assess the effects of a once-daily 400 mg dose ...
(Date:12/5/2016)... 5, 2016 According to a new market ... Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, ... market is projected to reach USD 779.8 Million by 2021 from ... during the forecast period of 2016 to 2021. ... ...
Breaking Medicine Technology: